<div id="readability-page-1"><div><p>As the United States market navigates a period of volatility, with major indexes closing lower amid concerns over an AI bubble and looming economic reports, investors are keenly observing the tech sector's dynamics. In such a climate, identifying high-growth tech stocks involves looking for companies with strong fundamentals and resilience to market pressures.</p><h3>Top 10 High Growth Tech Companies In The United States</h3><table><tbody><tr><th>Name</th><th>Revenue Growth</th><th>Earnings Growth</th><th>Growth Rating</th></tr><tr><td>ADMA Biologics</td><td>20.12%</td><td>23.48%</td><td>★★★★★☆</td></tr><tr><td>Marker Therapeutics</td><td>75.24%</td><td>59.07%</td><td>★★★★★★</td></tr><tr><td>Palantir Technologies</td><td>28.00%</td><td>32.57%</td><td>★★★★★★</td></tr><tr><td>Kiniksa Pharmaceuticals International</td><td>17.51%</td><td>33.44%</td><td>★★★★★☆</td></tr><tr><td>Workday</td><td>11.15%</td><td>32.18%</td><td>★★★★★☆</td></tr><tr><td>Circle Internet Group</td><td>23.14%</td><td>84.30%</td><td>★★★★★☆</td></tr><tr><td>RenovoRx</td><td>71.45%</td><td>71.45%</td><td>★★★★★☆</td></tr><tr><td>Zscaler</td><td>15.85%</td><td>45.93%</td><td>★★★★★☆</td></tr><tr><td>Duos Technologies Group</td><td>53.36%</td><td>152.11%</td><td>★★★★★☆</td></tr><tr><td>Procore Technologies</td><td>11.76%</td><td>116.48%</td><td>★★★★★☆</td></tr></tbody></table><p>Click here to see the full list of 76 stocks from our US High Growth Tech and AI Stocks screener.</p><p>Here we highlight a subset of our preferred stocks from the screener.</p><h2>Precigen (PGEN)</h2><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p><p><strong>Overview:</strong> Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company focused on developing gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases, with a market cap of $1.35 billion.</p><p><strong>Operations:</strong> Precigen focuses on developing gene and cell therapies using precision technology to address diseases in immuno-oncology, autoimmune disorders, and infectious diseases.</p><p>Despite its current unprofitability, Precigen demonstrates promising growth potential with an expected revenue increase of 55.8% per year, outpacing the US market average of 10.5%. This growth is bolstered by significant advancements in biotechnology, as evidenced by the FDA approval of PAPZIMEOS™ for treating recurrent respiratory papillomatosis—a first in its class. The company's commitment to innovation is further highlighted by a substantial R&amp;D investment relative to its revenue, positioning it well for future breakthroughs and financial success in a competitive industry landscape.</p><ul><li>Click here and access our complete health analysis report to understand the dynamics of Precigen.</li><li>Gain insights into Precigen's past trends and performance with our Past report.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0fb7141f-fd80-4e2e-93e9-552be9c67d53/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0fb7141f-fd80-4e2e-93e9-552be9c67d53/chart/revenue-and-expenses-breakdown"/><figcaption>PGEN Revenue and Expenses Breakdown as at Dec 2025</figcaption></figure><h2>Roivant Sciences (ROIV)</h2><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p><p><strong>Overview:</strong> Roivant Sciences Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of medicines and technologies, with a market cap of $15.23 billion.</p><p><strong>Operations:</strong> Roivant Sciences focuses on the discovery, development, and commercialization of medicines and technologies, generating revenue primarily from these activities. The company has a market cap of $15.23 billion.</p><p>Roivant Sciences, amidst a challenging landscape, showcases robust potential with an anticipated 58.5% annual revenue growth, significantly outpacing the U.S. market's average of 10.6%. Despite current unprofitability, earnings are expected to surge by 46.44% annually. Recent strides include positive trial outcomes for Brepocitinib in dermatomyositis and ongoing Phase 2 trials for Mosliciguat in pulmonary hypertension, setting the stage for pivotal FDA filings and commercial launches slated for early 2026 and beyond. These developments underscore Roivant's commitment to addressing critical medical needs through innovative therapies, positioning it favorably within the biotech sector's future landscape.</p><ul><li>Click here to discover the nuances of Roivant Sciences with our detailed analytical health report.</li><li>Evaluate Roivant Sciences' historical performance by accessing our past performance report.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1d84a70b-7896-4d8a-a33c-af4937623fd1/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1d84a70b-7896-4d8a-a33c-af4937623fd1/chart/earnings-and-revenue-growth"/><figcaption>ROIV Earnings and Revenue Growth as at Dec 2025</figcaption></figure><h2>Semrush Holdings (SEMR)</h2><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p><p><strong>Overview:</strong> Semrush Holdings, Inc. offers an online visibility management SaaS platform operating in the United States, the United Kingdom, and internationally with a market cap of approximately $1.77 billion.</p><p><strong>Operations:</strong> The company generates revenue primarily through its software and programming segment, which brought in $428.63 million. Its operations focus on providing a comprehensive SaaS platform for online visibility management across various regions.</p><p>In a significant industry move, Semrush Holdings, recently acquired by Adobe for $2 billion, continues to innovate at the intersection of AI and search engine optimization. Despite a net loss this year, Semrush reported a robust revenue increase to $325.99 million, up from $274.17 million last year, underlining its resilience and adaptability in a rapidly evolving tech landscape. The launch of 'Semrush One' integrates traditional SEO with AI-driven search capabilities, promising enhanced online visibility across various platforms including major LLMs like ChatGPT. This strategic expansion not only diversifies Semrush's offerings but also positions it strongly within the digital marketing sphere as businesses increasingly rely on sophisticated tools to navigate the complexities of internet visibility and brand engagement.</p><ul><li>Unlock comprehensive insights into our analysis of Semrush Holdings stock in this health report.</li><li>Learn about Semrush Holdings'  historical performance.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ea1498cd-82af-446b-851a-9bbea9898ae1/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ea1498cd-82af-446b-851a-9bbea9898ae1/chart/revenue-and-expenses-breakdown"/><figcaption>SEMR Revenue and Expenses Breakdown as at Dec 2025</figcaption></figure><h2>Turning Ideas Into Actions</h2><ul><li>Click here to access our complete index of 76 US High Growth Tech and AI Stocks.</li><li>Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.</li><li>Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.</li></ul><h2>Searching for a Fresh Perspective?</h2><ul><li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li><li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li><li>Find companies with promising cash flow potential yet trading below their fair value.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data      and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your      financial situation. We aim to bring you long-term focused analysis driven by fundamental data.      Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.      Simply Wall St has no position in any stocks mentioned.</em></p><div><p>Mobile Infrastructure for Defense and Disaster</p><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p><p>Get the investor briefing before the next round of contracts</p><p><span>Sponsored On Behalf of CiTech</span></p></div></div></div>

PLTR

<p>The article highlights high-growth tech stocks in the US amid market volatility, focusing on companies with strong fundamentals. It lists top companies like ADMA Biologics, Marker Therapeutics, and Palantir Technologies, noting their revenue and earnings growth. It also features Precigen, Roivant Sciences, and Semrush Holdings, detailing their operations and growth potential. The piece emphasizes the importance of innovation and strategic expansion in the tech sector, offering insights into investment opportunities through Simply Wall St's analysis tools.</p>

- The article discusses the performance of U.S. tech stocks amid market volatility, highlighting ten high-growth companies based on revenue and earnings growth.  
- Companies like ADMA Biologics, Marker Therapeutics, and Palantir Technologies showcase significant growth potential, driven by strong fundamentals and robust market strategies.  
- In particular, Precigen and Roivant Sciences are noted for their promising future prospects in the biotech sector, despite current unprofitability, due to innovative treatments and anticipated revenue increases.

US High Growth Tech Stocks To Watch December 2025